Skip to main content

News categories: Publication

New insights into our immune system

Bcl6 important for the formation of certain dendritic cells.

Dendritic cells play an important role in setting the course of our immune system. However, what determines their heterogeneity and functional specialization is still not sufficiently understood. An international collaboration consisting of researchers from the University Hospital Bonn (UKB), the University of Bonn and the Technical University of Denmark, among others, has investigated the role of the transcription factor Bcl6 in dendritic cells in a mouse model and discovered that a subgroup is highly dependent on this protein. The findings contribute to a better understanding of immunological processes during infections, vaccinations, allergies and autoimmunity. The results have now been published in the renowned scientific journal "Nature Communications".

Dendritic cells are part of our innate immune system and occupy a central position there. "These cells are particularly good at initiating an effective T-cell-mediated immune response of the acquired immune system," explains co-corresponding author Prof. Dirk Baumjohann from the Medical Clinic III for Hematology, Oncology, Immuno-Oncology and Rheumatology at the UKB, who is a member of the Cluster of Excellence ImmunoSensation2 and the Transdisciplinary Research Area (TRA) "Life & Health" at the University of Bonn. "However, it is still unclear what exactly drives their heterogeneity and functional specialization."

Previous studies have investigated the function of the protein Bcl6 in dendritic cells - in some cases with varying results. The aim of the current study is to harmonize the sometimes contradictory data using an in-depth analysis.

Bcl6 as an important transcription factor

The researchers therefore used a mouse model to investigate how the absence of Bcl6 affects all dendritic cell subgroups. "We found that in particular one specific dendritic cell subgroup (cDC2) is highly dependent on Bcl6," explains Prof. Katharina Lahl, who led the project at the Technical University of Denmark and is now continuing her work in Calgary. "Bcl6 deficiency leads to a lack of a dendritic cell subpopulation and results in impaired antibody responses in the spleen." As a result, the animals showed weakened immune responses in infection and vaccination models. "Bcl6 deficiency also led to the loss of the cDC2 subgroup in the large intestine, which caused a delayed recovery from an intestinal infection," adds Prof. Lahl.

In addition, the researchers were able to demonstrate with their study that the gene expression program in dendritic cells is already decisive for the subsequent cell fate of T cells and the associated immune response.

"The function of Bcl6 in dendritic cells overlaps with the already known function of Bcl6 in T cells and B cells and thus complements a gene expression program that acts synergistically across different immune cells," says Prof. Baumjohann. "These findings can contribute to the development of new therapeutic strategies, for example by strengthening specific dendritic cells during infection or vaccination or weakening them in allergies and autoimmune diseases."

Publication:

Hongkui Xiao, et al (2024)

Genomic deletion of Bcl6 differentially affects conventional dendritic cell subsets and compromises Tfh/Tfr/Th17 cell responses

Nature Communications, DOI: https://doi.org/10.1038/s41467-024-46966-6

Contact:

Prof. Dirk Baumjohann

Medical Clinic III for Haematology, Oncology, Immuno-oncology and Rheumatology

University Hospital Bonn

Cluster of Excellence ImmunoSensation2 & TRA "Life & Health", University of Bonn

E-mail: dirk.baumjohann@uni-bonn.de

Press release of the University of Bonn

Contact:

Johannes Seiler

Science editor

University of Bonn

E-Mail: j.seiler@uni-bonn.de

Related news

News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry
Wissenschaftler

News categories: Publication

Driver of inflammation after mild head injury

Mild traumatic brain injuries can lead to persistent memory problems and an increased risk of dementia. Yet, effective therapies to counteract these long-term consequences are still lacking. Dr. Dr. Sergio Castro-Gomez, Early Career Research Group Leader at the Institute of Physiology II of the University Hospital Bonn has discovered together with colleagues that the ASC protein. The research team hopes to identify new targets for future therapeutic strategies. The study, published in the Journal of Clinical Investigation, lays the foundation for upcoming clinical trials.
View entry
PM Immunity Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.
View entry

Back to the news overview